MARKET

PHIOW

PHIO PHARMACTCL
PHIOW
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-0.0572
0.5088
0.0124
-
BRIEF-Phio Pharmaceuticals Announces Regulatory Clearance Of Clinical Trial For PH-762 To Treat Melanoma
reuters.com · 01/11 12:47
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has received regulatory...
PR Newswire · 01/11 12:30
Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Office...
PR Newswire · 01/03 12:30
Analysts Expect Breakeven For Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Before Long
Phio Pharmaceuticals Corp. ( NASDAQ:PHIO ) is possibly approaching a major achievement in its business, so we would...
Simply Wall St. · 12/06/2021 14:28
Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual Meeting
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new study data at the Society f...
PR Newswire · 11/12/2021 12:00
BRIEF-Phio Pharmaceuticals Posts Q3 Loss Per Share Of $0.28
reuters.com · 11/10/2021 23:28
Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the qu...
PR Newswire · 11/10/2021 21:40
Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that new data suggesting a syst...
PR Newswire · 10/18/2021 11:05
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHIOW. Analyze the recent business situations of PHIO PHARMACTCL through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
-0.34-0.25-0.17-0.08
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Non-Executive Chairman/Independent Director
Robert Bitterman
President/Chief Executive Officer
Gerrit Dispersyn
Independent Director
Geert Cauwenbergh
Independent Director
H. Paul Dorman
Independent Director
Robert Ferrara
Independent Director
Jonathan Freeman
Independent Director
Curtis Lockshin
No Data

Webull offers kinds of PHIO PHARMACTCL stock information, including NASDAQ:PHIOW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIOW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHIOW stock methods without spending real money on the virtual paper trading platform.